Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of “Buy” from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned a consensus recommendation of “Buy” from the ten research firms that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $65.44.

Several equities analysts have commented on VERA shares. Wells Fargo & Company began coverage on shares of Vera Therapeutics in a research report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. Wolfe Research initiated coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an “outperform” rating and a $49.00 price target for the company. Wedbush lifted their target price on Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. Guggenheim increased their price target on Vera Therapeutics from $56.00 to $64.00 and gave the company a “buy” rating in a report on Monday, October 28th. Finally, JPMorgan Chase & Co. raised their price target on Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th.

Insider Buying and Selling

In related news, CEO Marshall Fordyce sold 17,500 shares of Vera Therapeutics stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares in the company, valued at $3,701,521.94. This trade represents a 16.92 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 52,500 shares of company stock valued at $2,305,625. Insiders own 21.70% of the company’s stock.

Institutional Trading of Vera Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of VERA. Mirae Asset Global Investments Co. Ltd. raised its position in Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock valued at $86,000 after purchasing an additional 350 shares in the last quarter. Huntington National Bank bought a new stake in shares of Vera Therapeutics in the fourth quarter valued at about $26,000. Ameritas Investment Partners Inc. raised its holdings in shares of Vera Therapeutics by 16.0% in the fourth quarter. Ameritas Investment Partners Inc. now owns 4,639 shares of the company’s stock valued at $196,000 after acquiring an additional 639 shares in the last quarter. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the fourth quarter valued at about $34,000. Finally, Alliancebernstein L.P. raised its holdings in shares of Vera Therapeutics by 2.0% in the fourth quarter. Alliancebernstein L.P. now owns 40,350 shares of the company’s stock valued at $1,706,000 after acquiring an additional 800 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 19.7 %

NASDAQ VERA opened at $27.46 on Friday. Vera Therapeutics has a one year low of $25.99 and a one year high of $51.61. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a 50 day moving average price of $38.91 and a 200-day moving average price of $40.85. The company has a market capitalization of $1.74 billion, a P/E ratio of -10.52 and a beta of 1.11.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.